The developed immunoplatform achieved a LOD value of 2.4 pg mL−1 MMP-9, and the method was applied to the determination of endogenous MMP-9 in both cancer cell lysates and serum samples of patients diagnosed with different subtypes of breast cancer [95]. Here, MMP9 is linked to breast cancer.